Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: March 12, 2008
Last updated: December 29, 2010
Last verified: December 2010
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.

Condition Intervention Phase
Ocular Hypertension
Drug: latanoprost
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Plasma latanoprost acid concentrations at steady-state. [ Time Frame: 2 weeks ]

Secondary Outcome Measures:
  • Adverse events related to systemic exposure of latanoprost [ Time Frame: 1 Day ]

Enrollment: 47
Study Start Date: May 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: latanoprost
latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.

Detailed Description:
Pharmacokinetics and Safety

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks.
  • The pediatric subjects will be grouped by age (0 to <3 years, 3 to <12 years, 12 to 18 years).

Exclusion Criteria:

  • Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit.
  • History of ocular trauma or surgery in either eye within 14-days of the screening visit.
  • Use of continuous wear contact lenses.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00638742

United States, California
Pfizer Investigational Site
Artesia, California, United States, 90701
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30339
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
United States, Massachusetts
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27705
Pfizer Investigational Site
Koebenhavn OE, Denmark, 2100
Pfizer Investigational Site
Catania, Italy, 95123
Pfizer Investigational Site
Coimbra, Portugal, 3000-548
Pfizer Investigational Site
Lisboa, Portugal, 1169-097
South Africa
Pfizer Investigational Site
Mayfair West, South Africa, 2109
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Madrid, Spain, 28046
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc Identifier: NCT00638742     History of Changes
Other Study ID Numbers: A6111139
Study First Received: March 12, 2008
Last Updated: December 29, 2010

Keywords provided by Pfizer:
Latanoprost Pediatrics Pharmacokinetics Safety

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Antihypertensive Agents processed this record on April 28, 2017